Saxenda Prescription Calculation for Modified Dosing Regimen
For a 28-day regimen of Saxenda at 0.5 mg daily for 7 days followed by 1.2 mg daily for 21 days, prescribe 2 Saxenda pens (each pen contains 18 mg total, delivering 6 mg/mL in a 3 mL pen).
Dosage Calculation
Total medication needed:
- Week 1 (days 1-7): 0.5 mg × 7 days = 3.5 mg
- Weeks 2-4 (days 8-28): 1.2 mg × 21 days = 25.2 mg
- Total required: 28.7 mg 1
Pen capacity:
- Each Saxenda pen contains 18 mg total (6 mg/mL in 3 mL) 1
- One pen is insufficient (only 18 mg available)
- Two pens provide 36 mg total, which covers the 28.7 mg requirement with appropriate buffer 1
Important Prescribing Considerations
This regimen deviates from FDA-approved dosing: The standard Saxenda escalation schedule starts at 0.6 mg daily (not 0.5 mg) and progresses weekly through 1.2 mg, 1.8 mg, 2.4 mg, to the target maintenance dose of 3 mg daily 1. Your proposed regimen stops at 1.2 mg, which is explicitly designated as a titration dose only, not a maintenance dose 1.
Clinical effectiveness concerns:
- The FDA label clearly states that 3 mg daily is the recommended maintenance dosage for adults, and lower dosages are for titration only 1
- Real-world data demonstrates significant weight loss even at submaximal doses (1.2-2.4 mg daily), though 3 mg remains the target 2
- Liraglutide 3.0 mg produces mean weight loss of approximately 5.6% from baseline, compared to 1.7% with placebo 3
Monitoring requirements if prescribing this modified regimen:
- Evaluate weight change at 16 weeks; discontinue if patient has not lost at least 4% of baseline body weight 1
- Monitor for gastrointestinal adverse effects (nausea occurs in approximately 8% of patients on liraglutide) 3
- Assess hydration status, particularly if patient is on insulin or sulfonylureas 3
Critical Safety Warnings
Absolute contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC) 1
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1
- Serious hypersensitivity reactions to liraglutide 1
Common pitfall: If more than 3 days elapse between doses, reinitiate at 0.6 mg daily and follow the full escalation schedule to reduce gastrointestinal adverse reactions 1.